On Monday, SELLAS Life Sciences Group Inc (NASDAQ: SLS) was -5.56% drop from the session before settling in for the closing price of $1.26. A 52-week range for SLS has been $0.50 – $1.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 22.63% over the past five years. When this article was written, the company’s average yearly earnings per share was at 57.21%. With a float of $64.06 million, this company’s outstanding shares have now reached $64.33 million.
Let’s look at the performance matrix of the company that is accounted for 16 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
SELLAS Life Sciences Group Inc (SLS) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward SELLAS Life Sciences Group Inc stocks. The insider ownership of SELLAS Life Sciences Group Inc is 0.43%, while institutional ownership is 6.31%.
SELLAS Life Sciences Group Inc (SLS) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -0.33 earnings per share (EPS) during the time that was less than consensus figure (set at 0.03) by -0.36. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 57.21% per share during the next fiscal year.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) Trading Performance Indicators
You can see what SELLAS Life Sciences Group Inc (SLS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.92, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.46 in one year’s time.
Technical Analysis of SELLAS Life Sciences Group Inc (SLS)
SELLAS Life Sciences Group Inc (NASDAQ: SLS) saw its 5-day average volume 0.81 million, a negative change from its year-to-date volume of 1.1 million. As of the previous 9 days, the stock’s Stochastic %D was 57.41%. Additionally, its Average True Range was 0.07.
During the past 100 days, SELLAS Life Sciences Group Inc’s (SLS) raw stochastic average was set at 42.70%, which indicates a significant increase from 33.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.20% in the past 14 days, which was lower than the 62.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2562, while its 200-day Moving Average is $1.1561. Nevertheless, the first resistance level for the watch stands at $1.2399 in the near term. At $1.2899, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3198. If the price goes on to break the first support level at $1.1600, it is likely to go to the next support level at $1.1301. The third support level lies at $1.0801 if the price breaches the second support level.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) Key Stats
There are 57,755K outstanding shares of the company, which has a market capitalization of 76.55 million. As of now, sales total 0 K while income totals -37,340 K. Its latest quarter income was 0 K while its last quarter net income were -7,470 K.
